Renovorx Inc

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026